FILTERED RESULTS
FILTERS
Ads Top
•
·
·
FILTERED RESULTS
Orcel: If We Do Not Reach Control, We Will Take a Pause (Video)
Microsoft (MSFT) Stock: Dips Before Earnings as Analysts Question Heavy AI Capex Strategy
Kevin Warsh, Trump’s Pick to Lead Fed, Faces Senate at Tricky Moment
Supreme Court Reviews F.C.C.’s Enforcement Power Against Communications Companies
Baggage Fees Are Up. Here’s How to Avoid Them.
Will S&P 500 Open Up Or Down On April 21?
Refinitiv to delete profiles of politicians’ grandchildren after lawsuit
Three Ships Including an Iranian Vessel Cross Hormuz Strait
Genting Casino Launches Royal Ascot VIP Experience Promotion for Online Players
AMD (AMD) Stock: Pulls Back From Record High as Analysts Raise Price Targets on AI CPU Boom
Even Without Internet Access, Prisoners Are Trying to Benefit From A.I.
Tesla Q1 2026 Earnings Preview: Key Events From The Past Three Months
This Earth Day, let's celebrate that Canada's air quality is the cleanest it's been in 50 years
Alternative Views with Theta’s Ruud Smets
TikTok Makes Americans Want Chinese EVs They Can’t Have
In Full: UniCredit's Orcel on His Pursuit of Commerzbank (Video)
Brazilian Officials Push Regulatory Reform Over Gambling Prohibition Amid National Debt Crisis
Bally’s Intralot Eyes £225M Deal to Acquire Struggling Evoke Gaming Group
Romania’s ONJN Announces €5 Million Program to Combat Gambling Addiction
Euro Attracts Bullish Options Buyers as Currency Goes Off Script
Guindos Says ECB Needs to Be Prudent, Keep a Cool Head on Rates
India’s Central Bank Warns of Persistent Inflation as Mideast Conflict Drags On
Intel (INTC) Stock: Pulls Back From 25-Year High Ahead of AI-Driven Earnings Test
Morgan Stanley expects positive market reaction for UK power stocks following government reforms
Avanza sinks 6% as Danish expansion costs overshadow record Q1 profit
Spain’s trade deficit narrows 24% in Jan-Feb from same period a year ago
US dollar edges higher as Iran ceasefire deadline approaches
UK employers turn cautious after start of Iran war
Hims & Hers (HIMS) Stock: Extends Rally on FDA Peptide Optimism and Subscriber Growth
Bawag Plans Dividend Limit, SRTs to Help Fund Irish Deal
Indian Wind Turbine Giant Says Nation Set to Meet 2030 Target
Apple’s next chief John Ternus faces defining AI moment
Apple (AAPL) Shares Decline Following Tim Cook’s CEO Departure Announcement
Amazon (AMZN) Stock Surges on Massive $125 Billion Anthropic AI Deal
BOJ warns prolonged Mideast tensions could raise costs, corporate defaults
U.S.-Iran ceasefire deadline; Warsh confirmation hearings - what’s moving markets
Broadcom (AVGO) Stock: Climbs Toward $2 Trillion Milestone Amid AI Chip Competition Concerns
Iranian Tanker Enters Territorial Waters with Navy Support
ECB Vice President Calls for Caution on Interest Rates Amid Geopolitical Tensions
NVIDIA Faces Challenges to Long-Term Dominance Amid Increased Competition
Meta and CBRE Launch LevelUp Program to Train Fiber Technicians
Amneal Pharmaceuticals Adjusts Price Target Amid 2026 Guidance
US Stock Futures Edge Up as Traders Focus on Iran: Markets Wrap
IonQ Achieves Milestone in Quantum Networking Technology
Oracle Adjusts Fair Value Price Target Amid AI Growth and Market Pressures
Iranian TV Denies Reports of Delegation Arrival in Pakistan
Google (GOOGL) Stock: Boosts Chrome AI Reach with Gemini Launch in 7 Countries
Novel approach needed for UK’s sick and unemployed
BOJ TO HOLD RATE ON RATE HIKE IN APRIL:NIKKEI...
Halozyme and Vertex Pharmaceuticals Enter Collaboration for Hypercon™ Technology
Halozyme Therapeutics, Inc. has announced a global exclusive collaboration and license agreement with Vertex Pharmaceuticals through its subsidiary, Halozyme Hypercon, Inc. This agreement allows Vertex to utilize Halozyme's Hypercon™ technology for up to three drug targets.
Hypercon™ is a novel microparticle technology designed to enable the hyperconcentration of drugs and biologics. This advancement aims to enhance the delivery and efficacy of therapeutic agents, potentially improving treatment outcomes for patients.
The collaboration marks a significant step for both companies, as they seek to leverage innovative technologies to address unmet medical needs in various therapeutic areas.
© 2026 KLEA News. All Rights Reserved. This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.
Source: KLEA News